Skip to main content
. 2017 Jul 15;31(8):685–697. doi: 10.1007/s40263-017-0455-7

Fig. 3.

Fig. 3

Attention-Deficit/Hyperactivity Disorder Rating Scale with Adult Prompts (ADHD-RS-AP) total score (a) and Clinical Global Impressions-Improvement (CGI-I) score (b) by treatment week. MAS mixed amphetamine salts, SD standard deviation; *p < 0.001 for the least-squares mean treatment difference vs. placebo for the change from baseline in the ADHD-RS-AP total score at week 4 (based on the mixed-effects model for repeated measures, including treatment, visit, and the interaction of treatment with the visit as factors; with the relevant baseline score as a covariate; and with an adjustment for the interaction of the baseline score with the visit); p < 0.001 for the least-squares mean treatment difference vs. placebo for the CGI-I score at week 4 (based on the mixed-effects model for repeated measures, including treatment, visit, and the interaction of treatment with the visit as factors; with the relevant baseline score as a covariate; and with an adjustment for the interaction of the baseline score with the visit)